• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Peripheral artery disease and chronic kidney disease: clinical synergy to improve outcomes.外周动脉疾病与慢性肾脏病:改善预后的临床协同作用
Adv Chronic Kidney Dis. 2014 Nov;21(6):460-71. doi: 10.1053/j.ackd.2014.07.005. Epub 2014 Oct 24.
2
Peripheral artery disease and CKD: a focus on peripheral artery disease as a critical component of CKD care.外周动脉疾病与慢性肾脏病:关注外周动脉疾病作为慢性肾脏病治疗的关键组成部分。
Am J Kidney Dis. 2012 Oct;60(4):641-54. doi: 10.1053/j.ajkd.2012.02.340. Epub 2012 May 5.
3
Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication.血管外科学会下肢动脉粥样硬化闭塞性疾病实践指南:无症状疾病和间歇性跛行的管理
J Vasc Surg. 2015 Mar;61(3 Suppl):2S-41S. doi: 10.1016/j.jvs.2014.12.009. Epub 2015 Jan 28.
4
Impact of Kidney Disease on Peripheral Arterial Interventions: A Systematic Review and Meta-Analysis.肾脏疾病对周围动脉介入治疗的影响:系统评价和荟萃分析。
Am J Nephrol. 2020;51(7):527-533. doi: 10.1159/000508575. Epub 2020 Jun 22.
5
Endovascular treatment of lower extremity peripheral arterial disease.下肢外周动脉疾病的血管内治疗。
Trends Cardiovasc Med. 2016 Aug;26(6):495-512. doi: 10.1016/j.tcm.2016.02.007. Epub 2016 Mar 3.
6
Outcomes of lower extremity peripheral arterial interventions in patients with and without chronic kidney disease or end-stage renal disease.患有和未患有慢性肾脏病或终末期肾病的患者下肢外周动脉介入治疗的结果
J Cardiovasc Surg (Torino). 2023 Dec;64(6):624-633. doi: 10.23736/S0021-9509.23.12798-4. Epub 2023 Dec 11.
7
Systematic review and meta-analysis of outcomes of lower extremity peripheral arterial interventions in patients with and without chronic kidney disease or end-stage renal disease.系统评价和荟萃分析下肢外周动脉介入治疗在伴有或不伴有慢性肾脏病或终末期肾病患者中的疗效。
J Vasc Surg. 2021 Jan;73(1):331-340.e4. doi: 10.1016/j.jvs.2020.08.032. Epub 2020 Sep 1.
8
Upper Extremity Medial Arterial Calcification and Peripheral Artery Disease in Asymptomatic Patients With Chronic Kidney Disease in Predialysis Stage.透析前阶段慢性肾脏病无症状患者的上肢内侧动脉钙化与外周动脉疾病
Angiology. 2018 May;69(5):406-415. doi: 10.1177/0003319717725966. Epub 2017 Aug 21.
9
Peripheral Artery Disease: Its Adverse Consequences With and Without CKD.外周动脉疾病:合并和不合并 CKD 的不良后果。
Am J Kidney Dis. 2020 May;75(5):705-712. doi: 10.1053/j.ajkd.2019.08.028. Epub 2019 Dec 23.
10
Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease.关于外周动脉疾病更具盈利性策略的系统评价和荟萃分析。
Ann Med. 2014 Nov;46(7):475-89. doi: 10.3109/07853890.2014.932618. Epub 2014 Jul 21.

引用本文的文献

1
Comparison of Adenine-Induced Rat Models for Vascular Calcification in Chronic Kidney Disease.慢性肾脏病中腺嘌呤诱导的大鼠血管钙化模型的比较
Biology (Basel). 2025 Jul 4;14(7):814. doi: 10.3390/biology14070814.
2
Exercise therapy to improve mobility, active behaviour and quality of life of chronic kidney disease patients with peripheral artery disease: study protocol for the EXACT-CKDPAD multicentre randomised controlled trial.运动疗法改善慢性肾脏病合并外周动脉疾病患者的活动能力、主动行为和生活质量:EXACT-CKDPAD多中心随机对照试验的研究方案
BMJ Open Sport Exerc Med. 2025 Jul 15;11(3):e002740. doi: 10.1136/bmjsem-2025-002740. eCollection 2025.
3
Clinical management of peripheral arterial disease in chronic kidney disease-a comprehensive review from the European Renal Association CKD-MBD Working Group.慢性肾脏病患者外周动脉疾病的临床管理——欧洲肾脏协会慢性肾脏病-矿物质与骨异常工作组的全面综述
Clin Kidney J. 2025 Apr 7;18(5):sfaf089. doi: 10.1093/ckj/sfaf089. eCollection 2025 May.
4
Systemic outcomes of symptomatic peripheral artery disease patients with end-stage renal disease undergoing lower limb endovascular treatment: a propensity score-matched analysis.接受下肢血管腔内治疗的终末期肾病症状性外周动脉疾病患者的全身预后:一项倾向评分匹配分析
BMC Cardiovasc Disord. 2025 May 21;25(1):388. doi: 10.1186/s12872-025-04838-x.
5
Incidence and predictors of cardiovascular disease mortality and all-cause mortality in patients with type II diabetes with peripheral arterial disease.2型糖尿病合并外周动脉疾病患者心血管疾病死亡率和全因死亡率的发生率及预测因素
PLoS One. 2025 May 16;20(5):e0322502. doi: 10.1371/journal.pone.0322502. eCollection 2025.
6
Current Prognostic Biomarkers for Peripheral Arterial Disease: A Comprehensive Systematic Review of the Literature.外周动脉疾病的当前预后生物标志物:文献的全面系统综述
Metabolites. 2025 Mar 25;15(4):224. doi: 10.3390/metabo15040224.
7
The safety of indocyanine green in patients with advanced chronic kidney disease or kidney transplantation: a scoping review.吲哚菁绿在晚期慢性肾病或肾移植患者中的安全性:一项范围综述。
Ann Med Surg (Lond). 2024 Nov 18;87(3):1351-1359. doi: 10.1097/MS9.0000000000002713. eCollection 2025 Mar.
8
Correlation between chronic kidney disease and all-cause mortality in diabetic foot ulcers: evidence from the 1999-2004 national health and nutrition examination survey (NHANES).糖尿病足溃疡患者慢性肾脏病与全因死亡率的相关性:来自1999 - 2004年美国国家健康和营养检查调查(NHANES)的证据
Front Endocrinol (Lausanne). 2025 Mar 14;16:1533087. doi: 10.3389/fendo.2025.1533087. eCollection 2025.
9
Prognostic Value of Hospital Frailty Risk Score and Clinical Outcomes in Critical Limb-Threatening Ischemia and End-Stage Kidney Disease.医院衰弱风险评分对临界肢体缺血和终末期肾病的预后价值。
J Am Heart Assoc. 2024 Nov 5;13(21):e036963. doi: 10.1161/JAHA.124.036963. Epub 2024 Nov 4.
10
Prevalence and factors associated with the correlation between malnutrition and pain in hemodialysis patients.血液透析患者营养不良与疼痛相关性的流行状况及相关因素分析。
Sci Rep. 2024 Jun 27;14(1):14851. doi: 10.1038/s41598-024-65603-2.

本文引用的文献

1
Principles supporting dynamic clinical care teams: an American College of Physicians position paper.支持动态临床护理团队的原则:美国医师学会立场文件。
Ann Intern Med. 2013 Nov 5;159(9):620-6. doi: 10.7326/0003-4819-159-9-201311050-00710.
2
Screening for peripheral artery disease and cardiovascular disease risk assessment with the ankle-brachial index in adults: U.S. Preventive Services Task Force recommendation statement.成人踝臂指数用于外周动脉疾病和心血管疾病风险评估的筛查:美国预防服务工作组推荐声明。
Ann Intern Med. 2013 Sep 3;159(5):342-8. doi: 10.7326/0003-4819-159-5-201309030-00008.
3
Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis.2000 年和 2010 年全球外周动脉疾病患病率和危险因素的估计值比较:系统评价和分析。
Lancet. 2013 Oct 19;382(9901):1329-40. doi: 10.1016/S0140-6736(13)61249-0. Epub 2013 Aug 1.
4
Home-based walking exercise intervention in peripheral artery disease: a randomized clinical trial.基于家庭的步行锻炼干预在周围动脉疾病中的应用:一项随机临床试验。
JAMA. 2013 Jul 3;310(1):57-65. doi: 10.1001/jama.2013.7231.
5
The toe-brachial index in the diagnosis of peripheral arterial disease.足臂血压指数在周围动脉疾病诊断中的应用。
J Vasc Surg. 2013 Jul;58(1):231-8. doi: 10.1016/j.jvs.2013.03.044. Epub 2013 May 18.
6
Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50.外周动脉疾病患者应用Vorapaxar:TRA2°P-TIMI 50 研究结果。
Circulation. 2013 Apr 9;127(14):1522-9, 1529e1-6. doi: 10.1161/CIRCULATIONAHA.112.000679. Epub 2013 Mar 15.
7
KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update.KDIGO 临床实践指南:糖尿病与慢性肾脏病(2012 年更新版)
Am J Kidney Dis. 2012 Nov;60(5):850-86. doi: 10.1053/j.ajkd.2012.07.005.
8
Diagnosis and management of lower limb peripheral arterial disease: summary of NICE guidance.下肢外周动脉疾病的诊断与管理:英国国家卫生与临床优化研究所指南摘要
BMJ. 2012 Aug 8;345:e4947. doi: 10.1136/bmj.e4947.
9
Survival benefits of revascularization in patients with critical limb ischemia and renal insufficiency.血运重建对合并肾功能不全的严重肢体缺血患者的生存获益。
J Vasc Surg. 2012 Sep;56(3):737-45.e1. doi: 10.1016/j.jvs.2012.02.049. Epub 2012 Jun 6.
10
Risk factors for peripheral arterial disease among patients with chronic kidney disease.慢性肾脏病患者外周动脉疾病的风险因素。
Am J Cardiol. 2012 Jul 1;110(1):136-41. doi: 10.1016/j.amjcard.2012.02.061. Epub 2012 Mar 31.

外周动脉疾病与慢性肾脏病:改善预后的临床协同作用

Peripheral artery disease and chronic kidney disease: clinical synergy to improve outcomes.

作者信息

Garimella Pranav S, Hirsch Alan T

机构信息

Division of Nephrology, Tufts Medical Center, Boston, MA; and Lillehei Heart Institute and Cardiovascular Division, University of Minnesota Medical School, Minneapolis, MN.

Division of Nephrology, Tufts Medical Center, Boston, MA; and Lillehei Heart Institute and Cardiovascular Division, University of Minnesota Medical School, Minneapolis, MN.

出版信息

Adv Chronic Kidney Dis. 2014 Nov;21(6):460-71. doi: 10.1053/j.ackd.2014.07.005. Epub 2014 Oct 24.

DOI:10.1053/j.ackd.2014.07.005
PMID:25443571
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4254470/
Abstract

Persons with CKD are at a higher risk of developing peripheral artery disease (PAD) and its adverse health outcomes than individuals in the general population who have normal renal function. Classic atherosclerosis risk factors (eg, age, smoking, diabetes, hypertension, and hyperlipidemia) are common in patients with CKD, but CKD also imposes additional unique risk factors that promote arterial disease (eg, chronic inflammation, hypoalbuminemia, and a procalcific state). Current nephrology clinical practice is adversely affected by PAD diagnostic challenges, the complexities of managing 2 serious comorbid diseases, delayed vascular specialist referral, and slow PAD treatment initiation in patients with CKD. Persons with CKD are less likely to be provided recommended "optimal" PAD care. The knowledge that both limb and mortality outcomes are significantly worse in patients with CKD, especially those on dialysis, is not just a biologic fact but can serve as a care delivery call to action. Nephrologists can facilitate positive change. This article proposes that patients with PAD and CKD be strategically comanaged by care teams that encompass the skills to create and use evidence-based care pathways. This proposed collaborative multidisciplinary approach will include vascular medicine specialists, nephrologists, wound specialists, and mid-level providers. Just as clinical care quality metrics have served as the base for ESRD and acute MI quality improvement, it is time that such quality outcomes metrics be initiated for the large PAD-CKD population. This new system will identify and resolve key gaps in the current care model so that clinical outcomes improve within a cost-effective care frame for this vulnerable population.

摘要

与肾功能正常的普通人群相比,慢性肾脏病(CKD)患者发生外周动脉疾病(PAD)及其不良健康结局的风险更高。经典的动脉粥样硬化危险因素(如年龄、吸烟、糖尿病、高血压和高脂血症)在CKD患者中很常见,但CKD还带来了促进动脉疾病的额外独特危险因素(如慢性炎症、低白蛋白血症和钙化状态)。当前肾脏病临床实践受到PAD诊断挑战、管理两种严重合并症的复杂性、血管专科转诊延迟以及CKD患者PAD治疗启动缓慢的不利影响。CKD患者不太可能获得推荐的“最佳”PAD护理。CKD患者,尤其是透析患者的肢体和死亡率结局明显更差,这一认识不仅是一个生物学事实,还可作为采取护理行动的呼吁。肾病学家可以促进积极的改变。本文建议由具备创建和使用循证护理路径技能的护理团队对PAD和CKD患者进行策略性的联合管理。这种提议的多学科协作方法将包括血管医学专家、肾病学家、伤口专家和中级医疗人员。正如临床护理质量指标已成为终末期肾病(ESRD)和急性心肌梗死质量改善的基础一样,现在是时候为大量的PAD-CKD人群启动此类质量结局指标了。这个新系统将识别并解决当前护理模式中的关键差距,以便在这个弱势群体具有成本效益的护理框架内改善临床结局。